PSEN1 and Alzheimer disease: In conclusion, we delineated the metabolic disturbance in the plasma of APP/PS1 mice and investigated the overall therapeutic effect of GBLE on AD through UHPLC-MS/MS-based metabolomic and lipidomic approach.